- Home
- FCCO vs ACRS Comparison
FCCO vs ACRS Comparison
Compare FCCO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCCO | ACRS |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 311.0M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FCCO | ACRS |
|---|---|---|
| Price | $31.11 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 75.1K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | 36.46 | ★ 69.01 |
| EPS | ★ 2.47 | N/A |
| Revenue | $922,000.00 | ★ $1,683,000.00 |
| Revenue This Year | $30.67 | N/A |
| Revenue Next Year | $5.87 | $4.24 |
| P/E Ratio | $12.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.80 | $1.12 |
| 52 Week High | $31.51 | $4.89 |
Technical Indicators
Market Signals| Indicator | FCCO | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 62.86 |
| Support Level | $29.10 | $3.16 |
| Resistance Level | $31.25 | $4.89 |
| Average True Range (ATR) | 0.56 | 0.23 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 83.57 | 88.89 |
Price Performance
Historical ComparisonAbout FCCO First Community Corporation
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.